Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
NPJ Vaccines|December 19, 2025
Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS TrialTroy J Kemp, Kathy Baisley, John Changalucha, et al.
The Journal of Infectious Diseases|February 24, 2019
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and TanzaniaZacchaeus Anywaine, Hilary Whitworth, Pontiano Kaleebu, et al.
Health Technology Assessment (Winchester, England)|May 30, 2019
Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluationYemisi Takwoingi, Hilary Whitworth, Melanie Rees-Roberts, et al.
Journal of Thrombosis and Haemostasis : JTH|January 11, 2025
Systematic analysis of the design, methodology, and patient population characteristics of the pediatric direct oral anticoagulant trials of venous thromboembolism treatmentMarisol Betensky, Manuela Albisetti, Tina Biss, et al.
American Journal of Medical Genetics. Part A|October 16, 2021
A novel MBTPS2 variant associated with BRESHECK syndrome impairs sterol-regulated transcription and the endoplasmic reticulum stress responseAlanna Strong, Michael E March, Christopher J Cardinale, et al.
Thorax|May 17, 2018
Diabetes mellitus and latent tuberculosis infection: baseline analysis of a large UK cohortCharlotte Jackson, Jo Southern, Ajit Lalvani, et al.
The Lancet. Global Health|September 16, 2022
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trialKathy Baisley, Troy J Kemp, Aimée R Kreimer, et al.
Blood|April 25, 2021
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-CHilary Whitworth, Sarah E Sartain, Riten Kumar, et al.
The Lancet. Global Health|February 16, 2024
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trialsKathy Baisley, Troy J Kemp, Nelly R Mugo, et al.
The Lancet. Global Health|September 16, 2022
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trialDeborah Watson-Jones, John Changalucha, Hilary Whitworth, et al.
Pageof 4